University of Minnesota School of Public Health, 420 Delaware St SE, Mayo Building B681, Minneapolis, MN 55455, USA; Health, Homelessness, and Criminal Justice Lab, Hennepin Healthcare Research Institute, 701 Park Ave., Suite PP7.700, Minneapolis, MN 55415, USA.
Department of Human Development and Family Studies, The Pennsylvania State University, University Park, PA, USA.
J Subst Abuse Treat. 2022 Dec;143:108894. doi: 10.1016/j.jsat.2022.108894. Epub 2022 Sep 30.
Overdose deaths involving opioids and stimulants continue to reach unprecedented levels in the United States. Although significant attention has been paid to the relationship between prescription and illicit opioid use, little work has focused on the association between prescription and illicit stimulant use. Thus, this study explores characteristics of those who use or misuse prescription stimulants and/or opioids and associations with use of cocaine, methamphetamine, and heroin.
We used 2015-2020 data from the National Survey on Drug Use and Health. Using adjusted multivariable logistic regression, we estimated the associations between past year prescription stimulant or prescription opioid prescribed use and misuse; various demographic characteristics; and past-year cocaine, methamphetamine, or heroin use.
From 2015 to 2020, 4.9 and 9.8 million US adults annually reported misusing prescription stimulants and opioids, respectively. Individuals who misused prescription stimulants were more likely to be ages 18-25 (45.8 %; 95 % CI: 44.0-47.5) than individuals who misused prescription opioids (21.7 %; 95 % CI: 20.7-22.7). We observed higher rates of cocaine use among individuals reporting prescription stimulant misuse (12.0 %; 95 % CI: 11.0-12.9) compared to those reporting prescription opioid misuse (5.7 %; 95 % CI: 5.1-6.3, p < 0.001). Heroin use was more common among individuals with prescription opioid misuse (2.1 %; 95 % CI: 1.7-2.2) than prescription stimulant misuse (0.6 %; 95 % CI: 0.4-0.7, p < 0.001). However, rates of methamphetamine use among individuals with prescription stimulant misuse (2.4 %; 95 % CI: 1.9-3.0) did not differ from individuals with prescription opioid misuse (2.1 %; 95 % CI: 1.7-2.5, p = 0.67).
Prescription stimulant misuse, compared to prescription opioid misuse, was associated with higher levels of cocaine use but not methamphetamine use. Treatment providers should consider screening for other substance use disorders among people who report prescription stimulant use or misuse. Additional research should seek to understand the mechanism underlying the different associations between prescription stimulant misuse and cocaine or methamphetamine use.
在美国,涉及阿片类药物和兴奋剂的过量死亡继续达到前所未有的水平。尽管人们对处方类阿片类药物和非法阿片类药物使用之间的关系给予了极大关注,但很少有研究关注处方类兴奋剂和非法兴奋剂使用之间的关联。因此,本研究探讨了使用或滥用处方兴奋剂和/或阿片类药物人群的特征,以及与可卡因、冰毒和海洛因使用的关联。
我们使用了 2015 年至 2020 年全国毒品使用与健康调查的数据。使用调整后的多变量逻辑回归,我们估计了过去一年中处方兴奋剂或处方阿片类药物规定使用和滥用与各种人口统计学特征之间的关联;以及过去一年中可卡因、冰毒或海洛因的使用情况。
从 2015 年到 2020 年,每年有 490 万和 980 万美国成年人报告滥用处方兴奋剂和阿片类药物。滥用处方兴奋剂的人比滥用处方阿片类药物的人更年轻(45.8%;95%CI:44.0-47.5)。我们观察到,报告处方兴奋剂滥用的人使用可卡因的比率较高(12.0%;95%CI:11.0-12.9),而报告处方阿片类药物滥用的人使用可卡因的比率较低(5.7%;95%CI:5.1-6.3,p<0.001)。与处方阿片类药物滥用相比,海洛因在处方阿片类药物滥用者中更为常见(2.1%;95%CI:1.7-2.2),而在处方兴奋剂滥用者中则较为少见(0.6%;95%CI:0.4-0.7,p<0.001)。然而,与处方阿片类药物滥用者相比,报告处方兴奋剂滥用的人使用冰毒的比率(2.4%;95%CI:1.9-3.0)并没有差异(2.1%;95%CI:1.7-2.5,p=0.67)。
与处方阿片类药物滥用相比,处方兴奋剂滥用与可卡因使用水平较高相关,但与冰毒使用无关。治疗提供者应考虑对报告使用或滥用处方兴奋剂的人进行其他物质使用障碍的筛查。进一步的研究应寻求理解处方兴奋剂滥用与可卡因或冰毒使用之间不同关联的机制。